Atrovent Aerosol, Metered
NDC Package 0597-0087-17
Package Information
Atrovent (ipratropium bromide) aerosols is ipratropium is used to control and prevent symptoms (wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD which includes bronchitis and emphysema). This formulation utilizes a aerosol, metered delivery system. Marketed by Boehringer Ingelheim Pharmaceuticals, Inc., this product is identified by NDC 0597-0087 and is authorized under FDA application NDA021527.
Identification & Billing
- RxCUI: 836343 - ipratropium bromide 17 MCG/INHAL Metered Dose Inhaler, 200 Actuations
- RxCUI: 836343 - 200 ACTUAT ipratropium bromide 0.017 MG/ACTUAT Metered Dose Inhaler
- RxCUI: 836343 - ipratropium bromide 0.017 MG/ACTUAT Metered Dose Inhaler, 200 ACTUAT
- RxCUI: 836343 - ipratropium bromide 17 MCG/ACTUAT Metered Dose Inhaler, 200 ACTUAT
- RxCUI: 836368 - Atrovent HFA 17 MCG/INHAL Metered Dose Inhaler, 200 Actuations
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 0597 - Boehringer Ingelheim Pharmaceuticals, Inc.
- 0597-0087 - Atrovent
- 0597-0087-17 - 1 CANISTER in 1 CARTON / 200 AEROSOL, METERED in 1 CANISTER
- 0597-0087 - Atrovent
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 0597-0087-17 identifies a specific commercial package of 1 canister in 1 carton / 200 aerosol, metered in 1 canister of Atrovent Hfa, a human prescription drug labeled by Boehringer Ingelheim Pharmaceuticals, Inc.. This aerosol, metered is formulated for respiratory (inhalation) use and contains ipratropium bromide as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Boehringer Ingelheim Pharmaceuticals, Inc. on May 01, 2005. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
Ipratropium is used to control and prevent symptoms (wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD which includes bronchitis and emphysema). It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. For preventing symptoms of lung disease, this medication must be used regularly to be effective. Use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) for wheezing or sudden shortness of breath unless otherwise directed by your doctor. Ipratropium does not work as fast as your quick-relief inhaler, but may sometimes be used to relieve symptoms of wheezing or sudden shortness of breath if so prescribed by your doctor.
How is this Boehringer Ingelheim Pharmaceuticals, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 00597008717. Quantities are measured in per "gm or gram", products billed per gram are products measured by weight.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.